Daiwa Capital Markets initiated coverage on shares of Legend Biotech (NASDAQ:LEGN – Get Rating) in a research report sent to investors on Monday morning, The Fly reports. The firm issued a buy rating on the stock.
A number of other equities analysts have also recently commented on LEGN. Barclays boosted their price target on Legend Biotech from $65.00 to $90.00 in a report on Friday, May 19th. JPMorgan Chase & Co. raised their price target on shares of Legend Biotech from $65.00 to $76.00 and gave the company an overweight rating in a research note on Wednesday, April 19th. HC Wainwright upped their price objective on shares of Legend Biotech from $66.00 to $77.00 and gave the stock a buy rating in a research report on Thursday, April 20th. BMO Capital Markets raised their target price on shares of Legend Biotech from $79.00 to $90.00 in a research report on Tuesday, April 25th. Finally, BTIG Research increased their price target on Legend Biotech from $75.00 to $85.00 and gave the company a buy rating in a research note on Thursday, April 20th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $77.40.
Legend Biotech Price Performance
Shares of NASDAQ:LEGN opened at $63.28 on Monday. Legend Biotech has a 1 year low of $37.30 and a 1 year high of $73.30. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.84 and a quick ratio of 3.79. The company’s 50 day simple moving average is $59.13 and its 200 day simple moving average is $53.27.
Institutional Trading of Legend Biotech
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.